The Cell Analysis and Specimen Banking Core is designed to support the clinical and basic science projects by centralizing common procedures (Aim 1) and centralizing tissue and specimen banking procedures (Aim 2). These include sample acquisition, processing, characterization, banking, and distribution;cell sorting;and analytical flow cytometry. The Myeloma Institute for Research and Therapy (MIRT) annually treats nearly 5,000 patients from across the US and the world. From this extensive patient base, Core B banks thousands of patient specimens, many of which are serially collected throughout the course of a patient's disease and treatment. Centralized sample acquisition and storage, together with enhanced database capabilities, is a tremendous resource for program project investigators, as well as a highly efficient operation. It will allow us to track samples and maintain records of expected data for each sample used, thus increasing the efficiency of data collection for all projects. These activities of the core will be enhanced by a constantly updated integrated database. A priority list for sample distribution will be established by the Core Oversight Committee, composed of the program PI and Project Leaders, and will be updated periodically to accommodate requirements of the different projects, such as cell numbers, sample type, and patient characteristics. This mechanism will greatly increase the efficiency of sample utilization by the different projects. A centralized sample processing service will avoid the need to establish the procedures in each investigator's laboratory, providing for uniform procedures and efficient use of materials. The flow cytometry and cell-sorting services offered will provide state-of-the-art support to the projects in this program application, which will be augmented by the expertise of core personnel.

Public Health Relevance

Core B is a service core and its impact relates to the relevance of the projects and the program it serves. By offering sample acquisition, processing, distribution, and specimen banking, Core B provides uniformity of procedures and patient specimen resources to all projects in this P01

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA055819-19
Application #
8566720
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
19
Fiscal Year
2013
Total Cost
$458,587
Indirect Cost
$141,893
Name
University of Arkansas for Medical Sciences
Department
Type
DUNS #
122452563
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Mikulasova, Aneta; Wardell, Christopher P; Murison, Alexander et al. (2017) The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica 102:1617-1625
Rasche, Leo; Weinhold, Niels; Morgan, Gareth J et al. (2017) Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev 55:190-199
Rasche, L; Chavan, S S; Stephens, O W et al. (2017) Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun 8:268
Went, M; Sud, A; Law, P J et al. (2017) Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach. Blood Cancer J 7:e573
Schinke, Carolina; Hoering, Antje; Wang, Hongwei et al. (2017) The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica 102:e313-e316
Chavan, S S; He, J; Tytarenko, R et al. (2017) Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer J 7:e535
Sawyer, J R; Tian, E; Shaughnessy Jr, J D et al. (2017) Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Leukemia 31:637-644
Mohan, Meera; Samant, Rohan S; Yoon, Donghoon et al. (2017) Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. J Bone Miner Res 32:1261-1266
Rasche, Leo; Angtuaco, Edgardo; McDonald, James E et al. (2017) Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood 130:30-34
Stein, Caleb K; Pawlyn, Charlotte; Chavan, Shweta et al. (2017) The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. Oncotarget 8:27854-27867

Showing the most recent 10 out of 284 publications